Pain management has the most structurally complex prior-authorization process of any specialty. A spinal cord stimulator — the most effective intervention for many refractory pain conditions — requires multiple sequential authorizations, each with its own documentation requirements. Interventional procedures that should provide relief must navigate frequency limits, prior-procedure documentation, and step-therapy requirements for every repeat visit.
The clinical consequence, when any step in this chain fails or delays, is predictable: patients return to oral analgesics, including opioids, while the authorization process catches up.
The numbers in pain management
Dedicated pain management PA studies are limited, but the AMA’s 2024 Prior Authorization Physician Survey captures the cross-specialty burden — and the adverse-event signal is particularly relevant here:
- 29% of physicians report PA led to a serious adverse event.
- 82% say PA can lead patients to abandon treatment.
- 93% of physicians say PA delays patient care.
- 39 authorizations per physician per week, ~13 hours lost to them (AMA 2024).
For pain management, the 29% serious-adverse-event figure is not abstract. When an SCS trial is delayed by authorization and a patient spends additional months on high-dose opioids or in uncontrolled pain, the adverse event arrives through the gap the authorization created.
Why pain management is different
- Multi-stage SCS authorization. Spinal cord stimulator implantation requires sequential PA at each stage: conservative management documentation → psychological evaluation → trial authorization → trial response documentation → permanent implant authorization. A denial or delay at any step restarts the timeline, not just delays it by the duration of the review.
- Conservative management as a prerequisite, not a choice. Before any SCS trial authorization can be requested, payers require documented failure of physical therapy, injections, and pharmacotherapy — over a specific time period, in a specific format. The documentation requirement and the mandated trial period together often extend the path to implant by months beyond what clinical judgment would indicate.
- Frequency-limited procedures. Interventional procedures carry per-year limits that are enforced through the PA process. A patient who needs more injections than the limit allows must navigate a medical exception process — which requires its own documentation and review timeline.
- Per-payer criteria variation. One payer requires 3 months of conservative management before SCS trial authorization; another requires 6 months; another specifies particular trial medications. The same patient’s history gets assembled differently for each.
What it costs
The most direct clinical cost is opioid bridge therapy. When an SCS authorization is delayed and a patient remains on opioids they were trying to reduce, every additional month is a month of continued dependence, tolerance development, and the risks that accompany high-dose opioid management. The operational cost is high: multi-stage authorizations at roughly $10.81 per manually processed authorization (CAQH 2023) mean each SCS pathway generates multiple authorization charges, and each interventional procedure generates its own PA cycle. A practice running high SCS volume accumulates significant overhead managing sequential authorization stages across a patient panel.
How to cut the wait
SCS and interventional procedure authorization is stage-managed documentation: each step requires specific records assembled at the right moment in the pathway. Artificer Health:
- Manages the SCS authorization pathway as a tracked multi-stage process — conservative management through trial through permanent implant — surfacing what documentation is needed at each stage before the request is submitted.
- Assembles intervention documentation — prior procedure records, frequency history, clinical response, and the step-therapy evidence each payer requires for repeat authorizations.
- Matches to the payer’s criteria at each stage so the submission at each step is complete, and no stage fails for a missing document that delays the entire pathway.
For a patient who has already spent months in conservative management, cutting weeks from the SCS authorization pathway is the difference between manageable pain and months more of it.
Sources: AMA 2024 Prior Authorization Physician Survey (n=1,000); payer medical policies for spinal cord stimulators (multi-stage authorization, conservative management requirements, trial response criteria); CAQH 2023 Index.